Indications
Kyprolis in combination with daratumumab and dexamethasone, with lenalidomide and dexamethasone, or with dexamethasone alone is indicated for the treatment of adult patients with multiple myeloma who have received at least one prior therapy.
Composition
- Active substance
- carfilzomib
Official product information
The European public assessment report holds the summary of product characteristics and the package leaflet in every EU language.
Prognia shows this product information for reference and learning. It is not treatment advice and can lag behind the official text. Always check the current product information and local protocols before prescribing.
At a glance
- Medicine
- Kyprolis
- Active substance
- carfilzomib
- ATC code
- L01XX45
- Therapeutic area
- Multiple Myeloma
- Marketing authorisation holder
- Amgen Europe B.V.
- Status
- Authorised